CRPS is a disproportionate, regional pain syndrome of a limb that typically follows injury or surgery and features sensory, vasomotor, sudomotor/oedema, and motor/trophic changes. The prevalence after limb fracture/surgery varies widely (≈1–7% overall, higher in some distal radius cohorts) and early recognition with rehabilitation improves outcome. Important risk factors include fracture (especially wrist/ankle), immobilisation, high pain intensity, female sex and psychological distress; major complications are chronicdisability, dystonia/contracture, osteoporosis, and reduced return-to-work [2,14,10,6].
Definition
CRPS: persistent regional pain disproportionate to any inciting event, with clinical signs/symptoms in ≥2 of 4 domains (sensory, vasomotor, sudomotor/oedema, motor/trophic) after exclusion of better diagnoses (Budapest criteria). CRPS I vs II: type I without identifiable nerve injury; type II (causalgia) with definable nerve lesion. “Warm” vs “Cold” CRPS: phenotypes reflecting vasodilated (erythematous, warm; more inflammatory early) vs vasoconstricted (blue/cold; often later/chronic) presentations. Allodynia/hyperalgesia: pain to light touch/pinprick greater than expected; central sensitisation hallmark.
CRPS is a clinicaldiagnosis; imaging/labs are supportive or to exclude mimics, not required for diagnosis.
If features are purely neuropathic without autonomic/motor signs, consider isolated peripheral nerve injury rather than CRPS.
Multimechanistic: neurogenic inflammation (neuropeptides/cytokines), small-fibre dysfunction, autoantibody phenomena (subset), central sensitisation, and maladaptive cortical re-organisation [2,0].
Precipitating events: fracture, surgery, sprain, crush injury, rarely without major trauma; higher with distal radius/ankle injuries and prolonged immobilisation [2,10].
Prevention—early mobilisation, good fracture care, patient education; vitamin C 500 mg/d for 6 weeks after wrist fracture may reduce risk (evidence mixed) [3,19].
Pathophysiology
Inciting injury/surgery → intense nociceptive input + local neurogenic inflammation → vasomotor/sudomotor changes and oedema.
Autonomic dysregulation → “warm” (vasodilated) early phenotype; with time some progress to “cold” (vasoconstricted) phenotype with trophic change and dystonia [15].
Disuse from pain/fear → stiffness, weakness, contractures; bone demineralisation.
Not all patients follow the same path—phenotype (warm vs cold) can guide therapy emphasis (anti-inflammatory/activation vs aggressive desensitisation/contracture prevention) [15,2].
Clinical Manifestations
Pain: regional, continuous, disproportionate to injury; burning/deep ache; mechanical/thermal allodynia and hyperalgesia.
Vasomotor: temperature or colour asymmetry (warm/red or cold/blue).
Sudomotor/oedema: swelling, sweating asymmetry.
Motor/trophic: weakness, tremor/dystonia, decreased ROM, nail/hair/skin changes; neglect-like symptoms or motor imagery difficulty.
Erythromelalgia (heat/redness without trophic/motor changes).
If a clear single-nerve deficit is present, consider CRPS II or focal neuropathy and image/EMG accordingly.
Classification
Complex regional pain syndrome is classified under chronic primary pain according to the International Classification of Diseases, 11th Revision (ICD-11). Chronic Primary Pain ispain that persists for ≥3 months and is not better explained by another condition. It is considered a disease in its own right, often associated with emotional distress or functional disability. Examples of chronic primary pain:
Chronic primary musculoskeletal pain (e.g., non-specific low back pain)
Complex Regional pain syndrome classification
By nerve injury: CRPS I (no identifiable nerve lesion) vs CRPS II (definable nerve injury)
By temperature phenotype: Warm CRPS (vasodilated, often early) vs Cold CRPS (vasoconstricted, often chronic)
By course: acute/early (<3–6 mo) vs persistent/chronic.
Paediatric vs adult CRPS (management emphasis differs but Budapest criteria apply)
Treatment
Foundations
Education (biopsychosocial model)
Early limb use and functional restoration
Desensitisation
Graded motor imagery (GMI)/mirror therapy
Structured physiotherapy/occupational therapy with pacing and flare plans
Analgesic/neuropathic agents (individualised): short course oral corticosteroids early may help pain/oedema; bisphosphonates (e.g., neridronate IV or IM) reduce pain in CRPS-I (moderate evidence); consider gabapentinoids, TCAs/SNRIs; topical agents for focal allodynia; avoid long-term strong opioids [4,12,20,17].
Interventional (refractory, specialist)
Dorsal root ganglion (DRG) stimulation offers higher treatment success than conventional spinal cord stimulation (SCS) at 3–12 months in lower-limb CRPS;
SCS remains an option
Consider sympathetic blocks for selected warm/vasomotor-dominant cases
Ketamine infusions and IV lidocaine only in specialised centres with careful selection [3,1,9].
Prevention after fracture
Encourage early mobilisation
Vitamin C 500 mg daily for 6 weeks after wrist fracture may lower incidence though evidence is mixed
school reintegration; medications are adjunctive [2]. Remember: Functional restoration is the primary goal; medications and procedures are adjuncts, not substitutes [2,6].
Cold, chronic CRPS with contracture needs aggressive ROM/functional programmes and splinting; monitor for osteoporosis/disuse.
Many improve within the first year with early rehab
A subset progress to chronic cold CRPS with disability
Poor prognostic factors include delayed diagnosis/treatment, cold phenotype, high early pain, psychological distress, and prolonged immobilisation [2,15]
Early interdisciplinary care and return-to-function planning are the strongest modifiable prognostic lever.
References
Deer TR, Levy RM, Kramer J, et al. Therapy habituation at 12 months: dorsal root ganglion versus spinal cord stimulation in CRPS. J Pain. 2019;20(5):551–561. (Jpain)
Royal College of Physicians. Complex regional pain syndrome in adults (2nd ed.). London: RCP; 2018. (rcp.ac.uk)
Varenna M, Adami S, Sinigaglia L, et al. Treatment of CRPS-I with neridronate: randomized placebo-controlled trial. Rheumatology (Oxford). 2013;52(3):534–542. (Oxford Academic)
Limakatso K, Madden V, Parker R. Graded motor imagery and mirror therapy for CRPS: systematic review. Biomedicines. 2023;11(9):2140. (MDPI)
Ferraro MC, Cashin AG, Wand BM, et al. Interventions for treating pain and disability in adults with CRPS: overview of systematic reviews. Cochrane Database Syst Rev. 2023;CD009416. (Cochrane)
IASP. Complex Regional Pain Syndrome Special Interest Group. 2024. (IASP)
Harden RN, Bruehl S, Perez RS, et al. Validation of the Budapest Criteria for CRPS. Pain. 2010;150(2):268–274. (ScienceDirect, baycrest.echoontario.ca)
Pain Relief Foundation. Clinical practice guideline review of reviews for CRPS management (2022). (painrelieffoundation.org.uk)
Kim HS, Jang CY, Kim JH, et al. Incidence and risk factors for CRPS after radius fractures: meta-analysis. Arch Orthop Trauma Surg. 2023;143(11):6639–6652. (SpringerLink)
Birklein F, Schlereth T. Complex regional pain syndrome—phenotypic characteristics and mechanisms. Nat Rev Neurol. 2018;14(9):607–617. (Nature)
Varenna M, Zucchi F, Ghiringhelli D, et al. Intramuscular neridronate in CRPS-I: randomized double-blind trial. Pain Med. 2021;22(10):2349–2359. (SAGE Journals, Europe PMC)
Faculty of Pain Medicine (UK). Criteria for diagnosis of CRPS (Budapest). 2021. (Faculty of Pain Medicine)
Macfarlane GJ et al. CRPS epidemiology (summary). BMJ. 2015;351:h2730. (BMJ)
Bruehl S, et al. Evidence for warm and cold CRPS subtypes. Pain. 2016;157(8):1674–1683. (Lippincott Journals)
Ferraro et al. Cochrane—physiotherapy for CRPS (background). Cochrane Database Syst Rev. 2015;CD010853. (Cochrane Library)
Cochrane overview and RSDSA guideline sections on steroids/ketamine (2022–2023). (Cochrane, issp-pain.org)
BSSH link to RCP guideline summary. 2018. (bssh.ac.uk)
Song K, et al. Vitamin C for preventing/treated CRPS: updated evaluation. Front Surg. 2024;11:1473311. (ScienceDirect)
Discussion